Form 8-K - Current report:
SEC Accession No. 0001558370-20-011765
Filing Date
2020-10-27
Accepted
2020-10-27 07:03:32
Documents
13
Period of Report
2020-10-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kala-20201027x8k.htm   iXBRL 8-K 47426
2 EX-99.1 kala-20201027xex99d1.htm EX-99.1 21993
  Complete submission text file 0001558370-20-011765.txt   205151

Data Files

Seq Description Document Type Size
3 EX-101.SCH kala-20201027.xsd EX-101.SCH 3032
4 EX-101.LAB kala-20201027_lab.xml EX-101.LAB 16739
5 EX-101.PRE kala-20201027_pre.xml EX-101.PRE 10611
6 EXTRACTED XBRL INSTANCE DOCUMENT kala-20201027x8k_htm.xml XML 5111
Mailing Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472 781-996-5252
Kala Pharmaceuticals, Inc. (Filer) CIK: 0001479419 (see all company filings)

EIN.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38150 | Film No.: 201262011
SIC: 2834 Pharmaceutical Preparations